title: Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction.
abstract: The feasibility and possible advantages of intravenous bolus administration of recombinant tissue-type plasminogen activator (rt-PA) were investigated in 26 consecutive patients with early (less than 6 hours) evolving acute myocardial infarction. Either an intravenous infusion of 40 clot-lysis megaunits (cIMU) double-chain rt-PA over 1.5 hours followed by 20 cIMU over 5 hours (infusion group, n = 12) or 4 intravenous bolus injections of 10 cIMU at 20 minute intervals (bolus group, n = 14) were randomly administered. Coronary arteriography was performed before and at regular predefined intervals up to 90 minutes from the start of rt-PA administration, and at 24 hours. Acute recanalization of the infarct-related coronary artery was demonstrated in 7 of 12 patients (58%; 95% confidence interval 28 to 85%) in the infusion group and 11 of 14 patients (79%; 95% confidence interval 49 to 95%) in the bolus group (difference not significant). Two patients in the bolus group had reoccluded by 24 hours. Mean time from the start of rt-PA to patency of the infarct-related coronary artery was 39 +/- 6 (standard error of the mean) minutes in the infusion group and 28 +/- 6 minutes in the bolus group (p = 0.2). There were no significant differences in the minimum infarct-related coronary artery luminal diameter measured by computerized quantitative arteriography between the infusion group and the bolus group at 90 minutes or at 24 hours.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
authors.forename: M I
authors.initials: MI
authors.lastname: Khan
authors.forename: D R
authors.initials: DR
authors.lastname: Hackett
authors.forename: F
authors.initials: F
authors.lastname: Andreotti
authors.forename: G J
authors.initials: GJ
authors.lastname: Davies
authors.forename: T
authors.initials: T
authors.lastname: Regan
authors.forename: A W
authors.initials: AW
authors.lastname: Haider
authors.forename: E
authors.initials: E
authors.lastname: McFadden
authors.forename: P
authors.initials: P
authors.lastname: Halson
authors.forename: A
authors.initials: A
authors.lastname: Maseri
mesh_terms: D000328:Adult; D000368:Aged; D004796:Clinical Enzyme Tests; D017023:Coronary Angiography; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D010958:Plasminogen / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D010958:Plasminogen; D003402:Creatine Kinase; D010959:Tissue Plasminogen Activator